Fiche traitement
SBRT
Centre hospitalier de l'Université de Montréal (CHUM) • Cancer
Suivi actif
Phase 1/2
Résumé
SBRT est développé par Centre hospitalier de l'Université de Montréal (CHUM). Le traitement est actuellement en Phase 1/2. Il est associé à Cancer. Son objectif thérapeutique principal est Ralentissement de la progression. Le statut actuel est : suivi actif.
À vérifier
Ralentissement de la progression
Phase 1/2
Centre hospitalier de l'Université de Montréal (CHUM)
Canada
Immunotherapy targeting the PD-1/PD-L1 pathway had previously been shown to be efficacious in the treatment of patients with metastatic head and neck squamous cell carcinomas. Stereotactic Body Radiotherapy (SBRT) to metastatic lesions causes localized cancer cell killing and the release of cancer cell debris, which could stimulate the immune system in the presence of immunotherapy. The purpose of this study is to assess the tolerability and efficacy of combining Durvalumab (MEDI4736), Tremelimumab and SBRT in controlling cancer progression. SBRT will be administered to patients while they are receiving Durvalumab and Tremelimumab.
2026-08-13
Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique
Phase 1/2
Début phase actuelle
Non disponible dans les sources synchronisées
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé
Objectif scientifique de l’étude
classification automatique vérifiable
Ralentissement de la progression
Confiance automatique : 66%
Ce pourcentage n’est pas une probabilité de succès clinique.
Il mesure uniquement la force de la classification automatique de l’objectif scientifique. Le calcul part de 45 points, ajoute 7 points par unité de poids du mot-clé le plus fortement détecté, puis est plafonné à 95 %. Exemple : un score maximal de 2 donne 45 + (2 × 7) = 59 %.
Indices détectés : progression → Ralentissement de la progression, immune → Immunomodulation
Ce score est heuristique et doit être vérifié dans le protocole ou une publication.
Description affichée depuis l’essai compatible NCT03283605, afin d’éviter le mélange entre plusieurs indications d’une même molécule.
Aucune incohérence majeure détectée entre la maladie, l’objectif et la description.
Transparence et qualité de la fiche
données vérifiablesClassificationCohérente automatiquement
Confiance de la fiche100 %
Source principaleSource officielle ou publication indexée
Dernière vérification2026-08-13
Anomalies détectées0
Validation humaineValidation humaine non effectuée
Donnée issue d’une source
Donnée normalisée automatiquement
Interprétation algorithmique
Classification scientifique multi-axes
ne pas confondre statut et résultatÉtat de l’étudeTerminée
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable
Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.
Indicateurs factuels
sans score subjectifPhase enregistréePhase 1/2
Études associées1
Publications associées17
Statut consolidéSuivi actif
Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.
Historique factuel de la molécule
21 événement(s) daté(s)Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.
| Date | Événement | Source |
|---|---|---|
| 2018-07-17 | Début de l’étudeNCT03283605 | Registre d’essai clinique |
| 2024-12-31 | Fin de l’étude prévue / enregistréeNCT03283605 | Registre d’essai clinique |
| 2026-07-08 | PublicationAI-surrogate structure and dose correlation for left anterior descending artery in lung stereotactic body radiotherapy. | Journal of applied clinical medical physics |
| 2026-07-08 | PublicationCBCT based online daily adaptive treatment improves target coverage with limited benefit for OAR protection in SBRT prostate cancer. | Radiation oncology (London, England) |
| 2026-07-12 | PublicationThe ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors. | European urology open science |
| 2026-07-14 | PublicationLong-term pulmonary function decline after stereotactic body radiation therapy for lung tumors. | Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology |
| 2026-07-14 | PublicationRadiation-induced cardiac toxicity after SBRT for central and ultracentral lung tumors: A multicenter retrospective cohort study. | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology |
| 2026-07-14 | PublicationBaseline and dynamic neutrophil-to-lymphocyte ratio predicts overall survival in unresectable pancreatic cancer following dose-escalated SBRT: a ten-year longitudinal study. | Frontiers in molecular biosciences |
| 2026-08-13 | PublicationRadiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline. | Practical radiation oncology |
| 2026-08-13 | PublicationImmune-preserving radiotherapy and perioperative immunotherapy in stage III NSCLC: a narrative review of current management and future directions for IIIA/IIIB NSCLC. | Translational lung cancer research |
| 2026-08-13 | Dernière mise à jour des donnéesSBRT | Biomedical Watch |
| 2026-08-16 | Création de l’enregistrementNCT03283605 | Registre d’essai clinique |
| 2026-08-16 | PublicationRetrospective Analysis of Survival and Adverse Effects Associated With Stereotactic Body Radiation Therapy in 12 Dogs With Hepatocellular Carcinoma. | Veterinary and comparative oncology |
| 2026-08-16 | PublicationReducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies. | Prostate cancer and prostatic diseases |
| 2026-08-16 | PublicationDifferential Cytokine Profiles in Prostate Cancer Under Treatment: Implications for Prognosis and Synergistic Therapy Design. | Cancers |
| 2026-08-16 | PublicationComparative assessment of kV imaging air kerma for intrafraction prostate fiducial monitoring using three clinical systems. | Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) |
| 2026-08-16 | PublicationA multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial. | BMC cancer |
| 2026-08-16 | PublicationWorkflow and dosimetric results for direct-to-unit single-fraction adaptive lung SBRT delivered on the ONE-STOP prospective pilot clinical trial. | Clinical and translational radiation oncology |
| 2026-08-16 | PublicationAddition of pulsed electric field ablation to SBRT for lung tumors: effect on health-related quality of life. | Lung cancer management |
| 2026-08-16 | PublicationLocal delivery of SBRT and IL-12 to murine PDAC tumors modulates hematopoiesis. | Oncoimmunology |
| 2026-08-16 | PublicationNeoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. | Advances in radiation oncology |
Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés
1 essai(s)
Début phase actuelle
Non disponible dans les sources synchronisées
| NCT | Titre | Phase | Statut administratif | Pays | Sponsor |
|---|---|---|---|---|---|
| NCT03283605 | Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas | Phase 1/2 | COMPLETED | Canada | Centre hospitalier de l'Université de Montréal (CHUM) |
Publications liées
17 publication(s)Publications liées
17 publication(s)| Titre | PMID | DOI | Journal | Date |
|---|---|---|---|---|
| Retrospective Analysis of Survival and Adverse Effects Associated With Stereotactic Body Radiation Therapy in 12 Dogs With Hepatocellular Carcinoma. Voir source | 42002308 | 10.1111/vco.70071 | Veterinary and comparative oncology | |
| Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies. Voir source | 41437135 | 10.1038/s41391-025-01071-7 | Prostate cancer and prostatic diseases | |
| Differential Cytokine Profiles in Prostate Cancer Under Treatment: Implications for Prognosis and Synergistic Therapy Design. Voir source | 41899568 | 10.3390/cancers18060967 | Cancers | |
| Comparative assessment of kV imaging air kerma for intrafraction prostate fiducial monitoring using three clinical systems. Voir source | 42302590 | 10.1016/j.ejmp.2026.105860 | Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) | |
| A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial. Voir source | 32758188 | 10.1186/s12885-020-07231-3 | BMC cancer | |
| Workflow and dosimetric results for direct-to-unit single-fraction adaptive lung SBRT delivered on the ONE-STOP prospective pilot clinical trial. Voir source | 42592074 | 10.1016/j.ctro.2026.101249 | Clinical and translational radiation oncology | |
| Addition of pulsed electric field ablation to SBRT for lung tumors: effect on health-related quality of life. Voir source | 41783980 | 10.1080/17581966.2026.2635332 | Lung cancer management | |
| Local delivery of SBRT and IL-12 to murine PDAC tumors modulates hematopoiesis. Voir source | 42246474 | 10.1080/2162402X.2026.2682058 | Oncoimmunology | |
| Neoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. Voir source | 42571456 | 10.1016/j.adro.2026.102128 | Advances in radiation oncology | |
| Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline. Voir source | 42580553 | 10.1016/j.prro.2026.07.002 | Practical radiation oncology | |
| Immune-preserving radiotherapy and perioperative immunotherapy in stage III NSCLC: a narrative review of current management and future directions for IIIA/IIIB NSCLC. Voir source | 42583046 | 10.21037/tlcr-2025-aw-1135 | Translational lung cancer research | |
| Long-term pulmonary function decline after stereotactic body radiation therapy for lung tumors. Voir source | 42445710 | 10.5603/rpor.111335 | Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology | |
| Radiation-induced cardiac toxicity after SBRT for central and ultracentral lung tumors: A multicenter retrospective cohort study. Voir source | 42435816 | 10.1016/j.radonc.2026.111694 | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | |
| Baseline and dynamic neutrophil-to-lymphocyte ratio predicts overall survival in unresectable pancreatic cancer following dose-escalated SBRT: a ten-year longitudinal study. Voir source | 42440477 | 10.3389/fmolb.2026.1877894 | Frontiers in molecular biosciences | |
| The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors. Voir source | 42433301 | 10.1016/j.euros.2026.06.004 | European urology open science | |
| AI-surrogate structure and dose correlation for left anterior descending artery in lung stereotactic body radiotherapy. Voir source | 42418215 | 10.1002/acm2.70703 | Journal of applied clinical medical physics | |
| CBCT based online daily adaptive treatment improves target coverage with limited benefit for OAR protection in SBRT prostate cancer. Voir source | 42415083 | 10.1186/s13014-026-02888-9 | Radiation oncology (London, England) |
Sources officielles
liens de rechercheDernière mise à jour des données : 2026-08-13
Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.